title: Cholecystokinin is necessary for the expression of morphine conditioned place preference.
abstract: There is evidence that the neuropeptide cholecystokinin (CCK) is important for the rewarding effects of drugs of abuse. However, less is known regarding the role of CCK in drug seeking and craving. The present study investigated whether the CCK(B) antagonist L-365, 260 could block morphine-induced drug seeking using the conditioned place preference paradigm and whether the dopaminergic reward pathway contributes to the effect of L-365, 260 on expression of morphine place preference. We found that systemic administration of the CCK(B) antagonist L-365, 260 attenuates the expression of morphine-induced drug seeking as assessed using conditioned place preference (CPP) and shows that this effect is mediated by CCK(B) receptors in the anterior nucleus accumbens (NAcc). Additionally, we demonstrate that this effect is dependent on D(2) receptor activation in the anterior nucleus accumbens (NAcc). These results indicate that endogenous CCK modulates the incentive-salience of morphine-associated cues and suggest that CCK antagonists may be useful in the treatment of drug craving.
authors.affiliation: Department of Neurology, Box 0114, University of California at San Francisco, San Francisco, CA 94143, USA. jennifer.mitchell@ucsf.edu
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Mitchell
authors.forename: Lindsey J
authors.initials: LJ
authors.lastname: Bergren
authors.forename: Katherine S
authors.initials: KS
authors.lastname: Chen
authors.forename: Howard L
authors.initials: HL
authors.lastname: Fields
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D002766:Cholecystokinin / Q000502:physiology*; D003216:Conditioning, Operant / Q000187:drug effects*; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000503:physiopathology; D009714:Nucleus Accumbens / Q000378:metabolism; D010671:Phenylurea Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000819:agonists
chemical_list: D001570:Benzodiazepinones; D010671:Phenylurea Compounds; D043887:Receptor, Cholecystokinin B; D017448:Receptors, Dopamine D2; C058121:L 365260; D009020:Morphine; D002766:Cholecystokinin